Posted in | Nanomedicine | Nanobusiness

Alnylam Reports Final Phase I Clinical Study Results of Lipid Nanoparticle-Based ALN-TTR01

Tekmira Pharmaceuticals, a specialist in RNA interference (RNAi) therapeutics announced that Alnylam Pharmaceuticals has reported final results from its Phase I clinical study of an RNAi therapeutic for transthyretin (TTR) called ALN-TTR01 that uses Tekmira’s lipid nanoparticle delivery technology to treat TTR-mediated amyloidosis and is produced by Tekmira.

Alnylam Pharmaceuticals presented the latest results at the XIII International Symposium on Amyloidosis conducted in Groningen, The Netherlands. The company had reported interim results in late 2011. According to the results, ALN-TTR01 administration significantly lowered the serum levels of both mutant and wild-type TTR proteins in patients with ATTR. For a single dose, knockdown of the disease-causing TTR protein was long-lasting, quick and based on the dosage. The results demonstrated the safety and tolerability of ALN-TTR01.

Alnylam Pharmaceuticals is now involved in the development of a second drug candidate dubbed as ALN-TTR02, which also uses Tekmira's lipid nanoparticle delivery technology and is produced by Tekmira. Alnylam Pharmaceuticals has started a Phase I clinical study on ALN-TTR02 to assess the clinical activity, tolerability and safety of ALN-TTR02. The company anticipates presenting the results from this study during Q3 of this year.

Mark J. Murray, President and Chief Executive Officer at Tekmira Pharmaceuticals, stated that the company is happy that the latest results from the Phase 1 human clinical study of ALN-TTR01 exemplify the tolerability of Tekmira's lipid nanoparticle delivery technology and its significance in the advancement of RNAi products. The company continues its efforts to advance its lipid nanoparticle delivery platform to facilitate RNAi therapeutics for various clinical indications.

Source: http://www.tekmirapharm.com

G.P. Thomas

Written by

G.P. Thomas

Gary graduated from the University of Manchester with a first-class honours degree in Geochemistry and a Masters in Earth Sciences. After working in the Australian mining industry, Gary decided to hang up his geology boots and turn his hand to writing. When he isn't developing topical and informative content, Gary can usually be found playing his beloved guitar, or watching Aston Villa FC snatch defeat from the jaws of victory.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Thomas, G.P.. (2019, February 12). Alnylam Reports Final Phase I Clinical Study Results of Lipid Nanoparticle-Based ALN-TTR01. AZoNano. Retrieved on November 12, 2019 from https://www.azonano.com/news.aspx?newsID=24839.

  • MLA

    Thomas, G.P.. "Alnylam Reports Final Phase I Clinical Study Results of Lipid Nanoparticle-Based ALN-TTR01". AZoNano. 12 November 2019. <https://www.azonano.com/news.aspx?newsID=24839>.

  • Chicago

    Thomas, G.P.. "Alnylam Reports Final Phase I Clinical Study Results of Lipid Nanoparticle-Based ALN-TTR01". AZoNano. https://www.azonano.com/news.aspx?newsID=24839. (accessed November 12, 2019).

  • Harvard

    Thomas, G.P.. 2019. Alnylam Reports Final Phase I Clinical Study Results of Lipid Nanoparticle-Based ALN-TTR01. AZoNano, viewed 12 November 2019, https://www.azonano.com/news.aspx?newsID=24839.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Submit